Background: Prediabetes is an alarming condition to control and prevent from developing diabetes mellitus which occurs due to the change in lifestyle and food habits. Timely untreated prediabetes turn into type-2 diabetes mellitus within a year and systemic complications such as retinopathy, nephropathy, and neuropathy could occur and in later stage multi system damage could take place.

Aims: The ai of this study is to evaluate the efficacy of (therapeutic emesis) with and followed by oral administration of (herbal decoction) in the management of prediabetes.

Materials And Methods: After approval of IEC and registration under clinical trial registry of India, 20 patients suffering from prediabetes were registered in the trial. Diagnosis criteria were hemoglobin A1c (HBA1c), fasting blood sugar (FBS) and postprandial blood sugar (PPBS), and assessment criteria includes HBA1c, FBS, PPBS, along with improvement in (strength of digestion and metabolism), (physical strength) and (mental strength), relief sign and symptom of prediabetes (), and improvement in quality of life (SF-36 Score). Classical followed by oral administration of was done. Total duration of treatment was 45 days and last follow-up was done on the 120 day. Student's - test was used for the analysis of parametric data.

Results: After the treatment were observed that there is improvement in subjective as well as in objective parameters. Statistically highly significant result was observed in HBA1c (BT [day 0] Mean score 6.25 and AT [day 120] 5.63 [ < 0.001]), FBS (BT [day 0] mean score 120.05 and AT [day 120] 93.31 [ < 0.001]) and PPBS (BT [day 0] mean score 165.26 and AT [day 120] 112.84 [ < 0.001]), sign and symptoms of , and quality of life (SF-36 Score).

Conclusion: The present clinical study concludes that therapeutic emesis (bio purification) followed by as internal medicine shows significant result in treating prediabetes () safely and effectively also control and prevent developing diabetes mellitus. None of the patient converted to diabetes mellitus on the day 120.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893903PMC
http://dx.doi.org/10.4103/ayu.ayu_417_20DOI Listing

Publication Analysis

Top Keywords

diabetes mellitus
16
therapeutic emesis
12
[day score
12
[day 120]
12
efficacy therapeutic
8
herbal decoction
8
decoction management
8
clinical trial
8
control prevent
8
prevent developing
8

Similar Publications

The rise in antimicrobial resistance poses a significant threat to global health, particularly among diabetic patients who are prone to urinary tract infections (UTIs). Pathogens that cause UTI among diabetic patients exhibit significant multidrug resistance (MDR) patterns, necessitating more precise empirical treatment strategies..

View Article and Find Full Text PDF

Objective: We investigated associations between per- and polyfluoroalkyl substances (PFAS) and changes in diabetes indicators from pregnancy to 12 years after delivery among women with a history of gestational diabetes mellitus (GDM).

Research Design And Methods: Eighty Hispanic women with GDM history were followed from the third trimester of pregnancy to 12 years after delivery. Oral and intravenous glucose tolerance tests were conducted during follow-up.

View Article and Find Full Text PDF

Utility of a C-Spirulina Stable Isotope Gastric Emptying Breath Test in Diabetes Mellitus.

Neurogastroenterol Motil

January 2025

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Background: The carbon-13 spirulina gastric emptying breath test (GEBT) is approved to identify delayed, but not accelerated, gastric emptying (GE). We compared the utility of the GEBT to scintigraphy for diagnosing abnormal GE in patients with diabetes mellitus.

Methods: Twenty-eight patients with diabetes ate a 230-kcal test meal labeled with technetium 99 m and C-spirulina, after which 10 scintigraphic images and breath samples (baseline, 15, 30, 45, 60, 90, 120, 150, 180, 210, and 240 min) were collected on 2 occasions 1 week apart.

View Article and Find Full Text PDF

Emerging Immunotherapies for Disease Modification of Type 1 Diabetes.

Drugs

January 2025

Division of Endocrinology, Department of Pediatrics, College of Medicine, University of Florida, 1699 SW 16th Ave, Building A, Gainesville, FL, 32608, USA.

Type 1 diabetes mellitus (T1DM) is characterized by the progressive, autoimmune-mediated destruction of β cells. As such, restoring immunoregulation early in the disease course is sought to retain endogenous insulin production. Nevertheless, in the more than 100 years since the discovery of insulin, treatment of T1DM has focused primarily on hormone replacement and glucose monitoring.

View Article and Find Full Text PDF

An insight on the additive impact of type 2 diabetes mellitus and nonalcoholic fatty liver disease on cardiovascular consequences.

Mol Biol Rep

January 2025

Department of Pharmaceutical Sciences & Technology, BIT Mesra, Ranchi, 835215, India.

Background: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are associated with a multifactorial complicated aetiology that is often coexisting and has a strong and distinct connection with cardiovascular diseases (CVDs). In order to accomplish effective and appropriate therapeutic strategies, a deeper understanding of the bidirectional interaction between NAFLD patients, NAFLD patients with T2DM, and NAFLD patients with CVDs is required to control the concomitant rise in prevalence of these conditions worldwide. This article also aims to shed light on the epidemiology and mechanisms behind the relationship between T2DM, NAFLD and the related cardiovascular consequences.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!